Abstract
In test-negative design studies that use rapid tests to estimate influenza vaccine effectiveness (VE) a common concern is case/control misclassification due to imperfect test sensitivity and specificity. However, an imperfect test can also fail to exclude from the control group people that do not represent the source population, including people infected with other influenza types or other vaccine-preventable respiratory viruses for which vaccination status is correlated. We investigated these biases by comparing the effectiveness of seasonal 2023/24 influenza vaccination against influenza A and B based on PCR versus rapid test results, excluding controls who tested positive for SARS-CoV-2 or the other type of influenza. By PCR, VE against influenza A was 49% (95%CI 26–65%) after exclusion of PCR-confirmed influenza B and SARS-CoV-2 controls. Corresponding VE against influenza B was 65% (95%CI 35–81%). VE estimated by adjusting for COVID-19 vaccination status yielded similar estimates to the scenario that excluded SARS-CoV-2-positive controls. When case/control status and exclusions from test-negative controls were determined by rapid test, VE was reduced by 5–15 percentage points. Bias correction methods were able to reduce these discrepancies. When estimating VE from a test-negative study using rapid test results, methods to correct misclassification bias are recommended.
Competing Interest Statement
EP is involved in an estate that holds shares of Astra Zeneca. BJC consults for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Novavax, Pfizer, Roche and Sanofi Pasteur. SGS reports honoraria from CSL Seqirus, Evo Health, Moderna, Novavax and Pfizer. The authors report no other potential conflicts of interest.
Funding Statement
This project was supported by the Health and Medical Research Fund, Health Bureau, The Government of the Hong Kong Special Administrative Region (grant no. INF-HKU-3), the Theme-based Research Scheme (Project No. T11-712/19-N) of the Research Grants Council of the Hong Kong SAR Government, and the National Institute of General Medical Sciences (grant no. R01 GM139926). EP is supported by Finnish Medical Foundation. BJC is supported by an RGC Senior Research Fellowship from the University Grants Committee of Hong Kong (grant number: HKU SRFS2021-7S03).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received approval from the Institutional Review Board of the University of Hong Kong. Written informed consent was obtained for each participant and parental consent was obtained for participants below 18 years of age.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
